Pfizer (NYS: PFE) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Pfizer met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share grew significantly.
Margins increased across the board.
Pfizer logged revenue of $15.06 billion. The 13 analysts polled by S&P Capital IQ anticipated a top line of $14.91 billion on the same basis. GAAP reported sales were 11% lower than the prior-year quarter's $16.98 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.62. The 15 earnings estimates compiled by S&P Capital IQ anticipated $0.54 per share. GAAP EPS of $0.43 for Q2 were 30% higher than the prior-year quarter's $0.33 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 81.7%, 310 basis points better than the prior-year quarter. Operating margin was 31.0%, 190 basis points better than the prior-year quarter. Net margin was 21.6%, 620 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $14.87 billion. On the bottom line, the average EPS estimate is $0.56.
Next year's average estimate for revenue is $60.01 billion. The average EPS estimate is $2.21.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,490 members out of 6,082 rating the stock outperform, and 592 members rating it underperform. Among 1,532 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,429 give Pfizer a green thumbs-up, and 103 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.92.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
Add Pfizer to My Watchlist.
The article Pfizer Beats Analyst Estimates on EPS originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.